To test the hypothesis that targeting the soluble NKG2D ligand MIC enhances therapeutic efficacy of PD1 blockade, we randomized a cohort of B16F10-sMICB tumor-bearing mice into four therapeutic groups (n = 8–10 per group) with control IgGs (cIgG) in vehicle PBS, single-agent sMICB-targeting mAb B10G5 or anti-PDL1 mAb, or an antibody cocktail of B10G5 and anti-PDL1 mAb. Here, PDCD1 is linked to neoplasm.